Canadian Nuclear Medicine Market
Canada Nuclear Medicine Market Analysis Report 2024-2030, Featuring Nordion, Lantheus Medical Imaging, Cardinal Health, Jubilant Life Sciences, Isologic Innovative Radiopharmaceuticals & Curium Pharma
January 24, 2024 05:46 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Canada Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostic, Therapeutic), Application (Oncology, Bone Metastasis,...
POINT logo light blue (png).png
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
December 18, 2023 07:30 ET | POINT Biopharma
BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced...
TeleDaas_Logo_Colour FINAL.png
TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations
November 26, 2023 08:00 ET | TeleDaas PLLC
TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughs.
POINT logo light blue (png).png
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 13, 2023 07:30 ET | POINT Biopharma
INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
22157.jpg
Global Radiopharmaceuticals Strategic Analysis Report 2023: Market to Reach $14.3 Billion by 2030 - Emergence of Radiotheranostics as Dual-Functioning Radiopharmaceuticals Bolsters Growth
October 09, 2023 05:48 ET | Research and Markets
Dublin, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Radiopharmaceuticals Market...
POINT logo light blue (png).png
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
September 18, 2023 08:00 ET | POINT Biopharma
INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery,...
Global Radiopharmaceutical Theranostics Market
Radiopharmaceutical Theranostics Market Projected to Reach $3.44 Billion by 2028, Fueled by Growing Cancer Incidence and Personalized Medicine
September 18, 2023 07:48 ET | Research and Markets
Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The "Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Radioisotope, Source, Application,...
POINT logo light blue (png).png
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 14, 2023 07:30 ET | POINT Biopharma
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first...
POINT logo light blue (png).png
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
July 31, 2023 09:00 ET | POINT Biopharma
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc....
POINT logo light blue (png).png
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
June 26, 2023 07:45 ET | POINT Biopharma
INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and...